Lv1
10 积分 2024-02-28 加入
Mobocertinib (TAK-788): A Targeted Inhibitor ofEGFRExon 20 Insertion Mutants in Non–Small Cell Lung Cancer
1小时前
已完结
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer
1个月前
已完结
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
1个月前
已完结
Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer
2个月前
已完结
Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art
2个月前
已完结
Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
2个月前
已完结
The State of the Art of EGFR exon 20 insertions in non-small cell lung cancer: diagnosis and future perspectives
2个月前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
2个月前
已完结
507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC
2个月前
已完结
1210P Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
2个月前
已完结
皖公网安备34019202002308
